It is not unusual for drugs to fail Phase 3 pivotal studies after showing success in Phase 2 studies. In fact, it is the norm rather than the exception. And this reality is not limited to experimental drugs … almost every major anti-cancer drug on the market today has failed at least one pivotal study [...]
Comment 27 June
The wait is over, and no doubt everyone feels as gutted as I do. But before we slit our collective wrists, I urge some perspective. Novogen is, and has always been, a lot more than just PXD and OVATURE. That has been the focus of market attention, and the failure of the trial is what [...]
With the MSHL annual shareholders meeting out of the way, I have a few comments. I also note some comments on the Yahoo message board following the recent presentation which I will follow up on here. 1. On the departure of Chris Naughton, as I have said previously, I have no inside knowledge on the background to [...]